Stock Events

Stock Events

Inhibikase Therapeutics 

€2.5
0
+€0+0% Thursday 07:07

Statistics

Day High
2.5
Day Low
2.5
52W High
2.5
52W Low
2.5
Volume
0
Avg. Volume
0
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

18MayExpected
Q4 2025
Next
-0.09
-0.09
-0.09
-0.09
Expected EPS
-0.09245029887
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow IQT0.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap27.62B
Biogen has a strong portfolio in neurodegenerative diseases, directly competing with Inhibikase's Parkinson's and related disorders treatments.
Palatin Technologies
PTN
Mkt Cap35.85M
Palatin Technologies works on treatments for diseases with a focus on inflammatory and central nervous system diseases, overlapping with Inhibikase's therapeutic areas.
Acadia Pharmaceuticals
ACAD
Mkt Cap3.76B
Acadia Pharmaceuticals specializes in central nervous system disorders, including Parkinson’s disease psychosis, directly competing with Inhibikase.
Alkermes
ALKS
Mkt Cap5.69B
Alkermes focuses on central nervous system diseases, including treatments for neurological disorders, competing in the same therapeutic area as Inhibikase.
AMGEN
AMGN
Mkt Cap178B
Amgen has a broad focus on biologics in various therapeutic areas, including neurology, potentially competing with Inhibikase's pipeline.
Abbvie
ABBV
Mkt Cap365.43B
AbbVie has a strong presence in neuroscience, including Parkinson's disease treatments, making it a direct competitor to Inhibikase.
Astrazeneca
AZN
Mkt Cap286.4B
AstraZeneca has a diverse portfolio that includes treatments for neurological disorders, potentially competing with Inhibikase's focus areas.
Novartis
NVS
Mkt Cap279.67B
Novartis offers treatments for a wide range of health conditions, including neurological diseases, competing with Inhibikase's research and development focus.
Pfizer
PFE
Mkt Cap149.77B
Pfizer has a broad research portfolio that includes neuroscience, potentially putting it in competition with Inhibikase for market share in neurodegenerative disease treatments.

About

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.
Show more...
CEO
Mr. Mark T. Iwicki
Employees
15
Country
United States
ISIN
US45719W2052

Listings

STU
DE
IQT0.STU
MU
DE
IQT0.MU
XNAS
US
IKT
BOATS
BOATS
IKT.BOATS

0 Comments

Share your thoughts

FAQ

What is Inhibikase Therapeutics stock price today?▼
The current price of IQT0.MU is €2.5 EUR — it has increased by +0% in the past 24 hours. Watch Inhibikase Therapeutics stock price performance more closely on the chart.
What is Inhibikase Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Inhibikase Therapeutics stocks are traded under the ticker IQT0.MU.
When is the next Inhibikase Therapeutics earnings date?▼
Inhibikase Therapeutics is going to release the next earnings report on May 18, 2026.
What were Inhibikase Therapeutics earnings last quarter?▼
IQT0.MU earnings for the last quarter are -0.09 EUR per share, whereas the estimation was -0.09 EUR resulting in a +3.06% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Inhibikase Therapeutics have?▼
As of May 06, 2026, the company has 15 employees.
In which sector is Inhibikase Therapeutics located?▼
Inhibikase Therapeutics operates in the Health & Wellness sector.
When did Inhibikase Therapeutics complete a stock split?▼
Inhibikase Therapeutics has not had any recent stock splits.
Where is Inhibikase Therapeutics headquartered?▼
Inhibikase Therapeutics is headquartered in Wilmington, United States.